Doximity (DOCS) shares fell 3.15% following a disappointing fourth-quarter earnings report, bringing the stock’s decline to 56% year-to-date. Investors are increasingly concerned about the potential impact of artificial intelligence on Doximity’s business model, particularly regarding its Scribe and Ask products, which face competition from more established AI solutions. However, the company maintains a robust ecosystem, serving over 85% of U.S. physicians and all top 20 pharmaceutical manufacturers as clients.
Despite the AI-related uncertainties, Doximity’s integration of AI tools into its offerings could enhance its platform rather than undermine it. In Q4, nearly half of its active prescribers utilized AI solutions, indicating a strategic alignment with technological advancements. However, rising costs associated with AI investments led to margin pressure, a key point for investors to monitor.
With a current trading multiple of 15 times free cash flow and a strong cash position, Doximity presents a compelling buying opportunity, particularly as the pharmaceutical advertising sector is expected to recover.
Source: fool.com